Cellular immunotherapy, particularly CAR-T cells, has shown potential in the improvement of
outcomes in patients with refractory and recurrent malignancies of the blood. However …

The induced pluripotent stem cell (iPSC) technology has transformed in vitro research and
holds great promise to advance regenerative medicine. iPSCs have the capacity for an …

Background Systemic therapy is the primary treatment for advanced thymic malignancies.
However, there is an urgent need to improve clinical outcome. Personalized treatment …

Comprising only 1-10% of the circulating T cell population, γδT cells play a pivotal role in
cancer immunotherapy due to their unique amalgamation of innate and adaptive immune …

Background Chemokines are critical players in the local immune responses to tumors.
CCL17 (thymus and activation-regulated chemokine, TARC) and CCL22 (macrophage …

BACKGROUND Immature dendritic cells (imDCs) play an important role in the induction of
donor-specific transplant immunotolerance. However, these cells have limitations, such as …

Hematologic malignancies are the most common hematopoietic diseases and a major
public health concern. However, the mechanisms underlying myeloid tumors remain …